Novelties in Head and Neck Cancer Research and Treatment

Speaker: Amanda Psyrri

A. Psyrri provides expert analysis on results from the studies in squamous cell head and neck cancer, in particular phase II study with cabazitaxel in recurrent or metastatic setting, as well as comparison of PET CT guided active surveillance with planned neck dissection for locally advanced nodal metastases after primary chemoradiotherapy. She says that pembrolizumab is active in nasopharyngeal carcinoma.

Discussion Points

  1. Abstract #2800 from ECC 2015: Cabazitaxel in patients with refractory recurrent or metastatic Squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial UNICANCER ORL03. What is a rationale for the study? What are the key study results? What is the impact for current practice?   
  2. Abstract #2801 from ECC 2015: Antitumor activity and safety of pembrolizumab in patients with PD-L1–positive nasopharyngeal carcinoma: Interim results from a phase 1b study. What is a rationale for the study? What are the key study results? What is the impact for current practice?
  3. Abstract #LBA 11 from ECC 2015:Differences in the quality of life (QoL) and functional outcomes of treatment between HPV associated (HPV+) and HPV- patients receiving primary chemoradiotherapy in PET-NECK - a multi-centre randomised phase III controlled trial comparing PETCT guided active surveillance with planned neck dissection for locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cell cancer treated with primary radical chemoradiotherapy. What is a rationale for the study? What are the key study results? What is the impact for current practice?